Details of the Drug Combinations

General Information of This Drug (ID: DMKGM42)

Drug Name

BREQUINAR DMKGM42

Synonyms

Brequinar; 96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atovaquone + BREQUINAR	DC1KHX4	Atovaquone	DD2 (Cell Line: DD2)	[3]
BREQUINAR + Dihydroergotamine	DCPIY4C	Dihydroergotamine	DD2 (Cell Line: DD2)	[3]
BREQUINAR + MK-4815	DC6VOBB	MK-4815	DD2 (Cell Line: DD2)	[3]
BREQUINAR + Dihydroergotamine	DC83T2W	Dihydroergotamine	Hepatoblastoma (Cell Line: HB3)	[4]
BREQUINAR + Chloroquine	DCHG854	Chloroquine	Hepatoblastoma (Cell Line: HB3)	[4]
BREQUINAR + Atovaquone	DC223XE	Atovaquone	Hepatoblastoma (Cell Line: HB3)	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BREQUINAR + Dipyridamole	DCZXJZQ	Dipyridamole	COVID-19	[5]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04575038) CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 (CRISIS2). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT03760666) A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5	ClinicalTrials.gov (NCT05166876) Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19